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Department of Neurobiology, Yale School of Medicine, New Haven, Connecticut
The prefrontal cortex (PFC†) is among the most evolved brain regions, contributing to our
highest order cognitive abilities. It regulates behavior, thought, and emotion using working
memory. Many cognitive disorders involve impairments of the PFC. A century of discover-
ies at Yale Medical School has revealed the neurobiology of PFC cognitive functions, as
well as the molecular needs of these circuits. This work has led to the identification of ther-
apeutic targets to treat cognitive disorders. recent research has found that the noradren-
ergic α2A agonist guanfacine can improve PFC function by strengthening PFC network
connections via inhibition of cAMP-potassium channel signaling in postsynaptic spines.
Guanfacine is now being used to treat a variety of PFC cognitive disorders, including
Tourette’s Syndrome and Attention Deficit Hyperactivity Disorder (ADHD). This article re-
views the history of Yale discoveries on the neurobiology of PFC working memory function
and the identification of guanfacine for treating cognitive disorders. 
IntroductIon 
Cognitive  disorders  are  among  the
most challenging and disturbing ailments.
They can alter who a person is, limit his or
her success in school or work, interfere
with friendships, impair the ability to care
for themselves and others, and disrupt the
lives  of  families  and  loved  ones.  Even
worse, cognitive impairment can extend to
loss of insight and judgment ― the patient
denies that anything is wrong ― making
the situation even more difficult to treat.
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†Abbreviations: PFC, prefrontal cortex; DA, dopamine; dlPFC, dorsolateral prefrontal cor-
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HCN channel, Hyperpolarization-activated Cycle Nucleotide gated cation channel; PKA,
protein kinase A; DISC1, Disrupted In Schizophrenia; PDE4, phosphodiesterase 4; NIMH,
National Institute of Mental Health.
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phrenia, autism, agingCognitive disorders involve dysfunction of
the most highly evolved cortical regions, the
association cortices, with particular vulner-
abilities  in  the  prefrontal  cortex  (PFC).
Thus, understanding the biology of these
disorders is a daunting yet fascinating task.
Almost a century of research at Yale School
of Medicine has revealed the neurobiology
of PFC cognitive operations and has begun
to reveal the molecular needs of these cir-
cuits, with the goal of identifying potential
therapeutic  targets.  Recent  research  has
found that the noradrenergic α2A agonist
guanfacine  can  strengthen  PFC  network
connections and improve PFC regulation of
behavior, thought, and emotion. Based on
these discoveries in animals, guanfacine is
now being used to treat a variety of cogni-
tive disorders that benefit from strengthened
PFC function.
the hIGhlY evolved PreFrontAl
cortex
The PFC is one of the most evolved re-
gions of the brain (Figure 1A). The human
neocortex consists of the basic sensory and
motor areas, as well as the association areas
that subserve perception and cognition. The
neocortex contains six layers of neurons
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Figure 1. Prefrontal cortical (PFc) circuits mediating higher cognitive operations. A.The
PFC expands tremendously in brain evolution, comprising a very small proportion of the brain
in rodents such as the rat and increasing dramatically in primates, with special prominence in
the human brain. The PFC is highlighted in blue. An inset of the human dlPFC is shown at the
right; this Nissl-stained section shows the six layers of dlPFC. B. The dlPFC microcircuits sub-
serving working memory, discovered by Goldman-rakic (1995) [1]. Pyramidal cells in deep
layer III receive visuospatial information from the parietal association cortex. Pyramidal cells
with similar spatial inputs excite each other through connections on dendritic spines to maintain
persistent firing throughout the delay period. The spatial tuning of the neuron’s response is
sharpened by lateral inhibition from parvalbumin-containing GABAergic interneurons, such as
the Basket cell (B) shown in this figure. Note that chandelier cells also serve this function (not
shown). The red rectangle highlights an axo-spinous synapse enlarged in C and D. These dlPFC
microcircuits are the ones most afflicted in schizophrenia, where there is loss of neuropil (in-
cluding loss of dendritic spines) in deep layer III [100], and reduced parvalbumin GABAergic
function [101]. c. A working model of the cAMP-potassium channel signaling mechanisms in
spines that dynamically weaken synaptic efficacy and gate out network inputs to the neuron.
cAMP directly opens HCN channels, while cAMP activation of PKA signaling increases the open
state of KCNQ channels. cAMP generated by calcium build up, e.g., feedback fatigue via NMDA
or mGlur1/5, or actively generated by stress exposure, e.g., via D1 or β1 receptor stimulation.
d.NE or guanfacine stimulation of α2A receptors on spines inhibits cAMP production and closes
HCN and KCNQ channels, strengthening network connectivity, increasing neuronal PFC firing,
and thus improving PFC regulation of behavior, thought and emotion. See Figure 5 for data
supporting the model. C and D artistically adapted from Arnsten et al., 2010 [71].(Figure 1A), which are intricately intercon-
nected to form neural networks. The associ-
ation cortices expand tremendously in the
primate brain, and, of these, the PFC sub-
serves the highest order cognitive functions.
The PFC guides thought, actions, and emo-
tion using representational knowledge [1,2],
allowing us to marry the past to the future
using working memory [3]. PFC circuits
hold information “in mind” to provide the
foundation for abstract thought and mental
manipulation, what is often referred to as
our “mental sketch pad.” This represented
information serves as goals and plans for ac-
tion, the basis for the executive functions
[4,5]. The PFC allows us to organize and
plan for long-term ambitions (career plans,
carrying out large projects) as well as very
short-term goals (holding together the be-
ginning and end of a sentence) to provide di-
rected meaning and a purposeful life [6].
The PFC protects goal-directed behavior
from distractions and compulsions [7] and
thus is essential for self-control, generating
the informed inhibition that is central to civ-
ilized behavior [8]. It is key for high order
decision-making  [9]  and  meta-cognition,
e.g., remembering to remember as well as
self-awareness (knowing what you know
and what you don’t know [10], knowing
what others are thinking [11], and moral
conscience [12]). The PFC accomplishes
these cognitive feats in a topographically or-
ganized manner, with dorsal and lateral PFC
circuits regulating attention, thought, and ac-
tion [13] and the more ventral and medial
PFC circuits regulating emotion and physi-
ological state [14]. There are likely other or-
ganizational  topographies  as  well,  e.g.,
increasingly abstract operations being per-
formed by increasingly rostral regions of
PFC [15]. It is remarkable that the neurobi-
ology of these highest order cognitive func-
tions has begun to be understood, and much
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Figure 2. the discovery of the key role of the dlPFc in working memory by Jacobsen
in 1936 [16]. A. Carlyle Jacobsen, in about 1940, who later became the first President of
SuNY upstate Medical Center. Photo courtesy of the F.W. Kent Collection of Photographs,
university of Iowa Archives, university of Iowa Libraries. B.An artistic rendering based on a
figure from Jacobsen’s paper showing the bilateral dlPFC lesion that gravely impaired spa-
tial working memory. unilateral PFC lesions or lesions of the same size elsewhere in the
cortex had much less effect on performance. c. reconstruction of a portion of a table from
Jacobsen’s paper showing the marked impairment on the delayed response spatial working
memory task and preserved performance on the visual discrimination problems that did not
require working memory to solve.of this success has arisen based on the pri-
mary studies at Yale School of Medicine.
the essentIAl role oF the 
PreFrontAl cortex In 
workInG memorY: the orIGInAl
dIscoverY BY JAcoBsen And
Fulton
The first groundbreaking studies of the
PFC’s role in cognition began in the 1930s
at Yale School of Medicine. John Fulton ar-
rived at Yale in 1930 to serve as Chair of the
new Department of Physiology. He had been
trained as a neurosurgeon by Harvey Cush-
ing at Harvard and was able to perform com-
plex surgeries that opened new avenues of
research. Together with Carlyle Jacobsen
(Figure 2A), they examined the effects of
specific brain lesions on behavior in pri-
mates. Although they are widely known for
their work relevant to lobotomies, i.e., that
very large PFC lesions made aggressive an-
imals calmer, their most important break-
through is rarely cited: the discovery that the
dorsolateral region of the PFC is essential for
abstract thought [16]. Jacobsen published
this finding in 1936 (citing the key role of
Fulton’s neurosurgical skills). He had de-
signed a definitive study comparing the ef-
fects of specific cortical lesions on a series
of cognitive tasks during which the informa-
tion needed to solve the problem was either
available in the environment or had to be
held  in  working  memory.  He  found  that
monkeys with bilateral lesions to the dorso-
lateral PFC (dlPFC), but not other cortical le-
sions, were markedly impaired on problems
requiring working memory and that this im-
pairment was permanent (Figure 2B-C). He
wrote, “The animal without the frontal asso-
ciation area learns and retains sensory-motor
habits and visual discriminations but it is un-
able to remember for even a few seconds
under which of two cups a piece of food is
concealed . . . It is as if ‘out of sight, out of
mind’ were literally applicable” [16].
World War II interrupted this extraordi-
nary research, but the work continued in the
1950s and 1960s, when researchers such as
Karl  Pribram  and  Mortimer  Mishkin  per-
formed lesion studies at Yale and further de-
fined the roles of PFC subregions in cognitive
performance [17], including work showing
the importance of PFC for resisting distrac-
tion [18] and the key roles of the sensory as-
sociation cortices for object perception [19]. 
the neuroBIoloGY oF
thouGht: the PIoneerInG
work oF GoldmAn-rAkIc
Patricia Goldman-Rakic began her ca-
reer in neuroscience performing develop-
mental and lesion studies at the National
Institute of Mental Health (NIMH), but then
moved to Yale, where she illuminated the
physiology, micro-circuitry ,and neuromod-
ulation of the brain networks underlying spa-
tial working memory (Figure 3A). Early in
her career at the NIMH, she further refined
Jacobsen’s work and defined the essential
PFC subregion needed for visuospatial work-
ing memory: the caudal two-thirds of the
principal  sulcal  dlPFC  [20,21].  She  then
went on to study the circuitry, physiology,
and modulatory needs of this PFC region,
performing most of this work at Yale. She
found parallel, reciprocal circuits between
the dlPFC and the sensory association cor-
tices, where projections from visuospatial,
visual feature, auditory spatial, and auditory
feature association cortices occupied distinct
domains in the dlPFC, with the spatial infor-
mation residing more dorsally and the fea-
ture  information  more  ventrally  [13].  In
particular, the visuospatial projections from
parietal area 7 terminated in the subregion of
dlPFC area 46 that she showed to be essen-
tial for visuospatial working memory [22].
These data indicated a specific topography
of anatomical projections even for the high-
est order cognitive abilities.
Goldman-Rakic’s group adapted an ear-
lier task [23] “to explore the full perimetry of
visual space” and reveal the cellular basis of
visuospatial  working  memory  [24].  They
recorded from area 46 of the dlPFC while
monkeys performed an oculomotor spatial
working memory task that required them to
remember one of eight ever-changing loca-
tions over a brief delay. Earlier studies had
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firing across the delay period while the mon-
key remembers the spatial position. This new
task  allowed  Goldman-Rakic  to  see  that
dlPFC Delay Cells are able to represent visu-
ospatial position, e.g., a neuron that contin-
ued to fire throughout the delay period if the
cue had appeared at 270ﾺ but not other loca-
tions, for example, the neural representation
of visual space (Figure 3B). Goldman-Rakic
then uncovered the dlPFC microcircuits that
create this neural representation (reviewed in
[1]). She showed that persistent firing across
the delay period is generated by columns of
pyramidal cells in deep layer III that excite
each other to maintain firing in the absence
of visual stimulation (Figure 1B), while the
precise spatial tuning (e.g., firing to represent
270ﾺ but not 90ﾺ) is sculpted by lateral inhibi-
tion from parvalbumin-containing GABAer-
gic interneurons, i.e., basket and chandelier
cells (Figure 1B). These layer III microcir-
cuits are the ones that expand most in primate
evolution [25] and are the focus of neuropil
loss in schizophrenia [26].
Goldman-Rakic  also  made  the  land-
mark discovery that dopamine (DA) inputs
onto PFC neurons (Figure 3C) have a criti-
cal modulatory influence on dlPFC spatial
working memory function and that depletion
of DA [27] or blockade of DA D1 receptors
[28] in the dlPFC produced spatial working
memory deficits as profound as ablation of
the cortex itself. This was the first indication
that dlPFC was absolutely dependent on the
correct neurochemical environment. Arnsten
and Goldman-Rakic then discovered that
very high levels of DA release, as occurs
during stress [29] or with drugs of abuse
[30], was as detrimental to working memory
function as was too little DA, the DA “in-
verted  U”  [31-34].  As  DA  signaling  is
known to be dysregulated in schizophrenia
[35,36], changes in DA modulation com-
bined with altered layer III microcircuits
likely underlie the profound PFC cognitive
deficits observed in this illness [37,38].
Although DA plays key roles in PFC
circuits, Arnsten and Goldman-Rakic dis-
covered that norepinephrine (NE) is equally
important for proper PFC function via its ac-
tions at post-synaptic, α2A adrenergic re-
ceptors [39] and that this receptor may be
especially amenable as a therapeutic target. 
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Figure 3. the discovery of the neurobiology of thought by Patricia Goldman-rakic. A.
Patricia Goldman-rakic about 2000. B. A dlPFC Delay Cell whose firing patterns represent
a precise portion of visual space. The neuron fired throughout the delay period if the cue
had occurred at 270ﾺ but did not fire if the cue had occurred at other spatial locations. Gold-
man-rakic [1] discovered the microcircuitry underlying the two key physiological features
needed for working memory: 1) persistent firing throughout the delay period, generated by
recurrent excitation in pyramidal cell microcircuits (Figure 1B), and 2) spatial tuning, sculpted
in part via lateral inhibition from GABAergic, parvalbumin-containing interneurons such as the
Basket cell depicted in Figure 1B. Artistically rendered based on Funahashi et al., 1989 [24].
c. Dopamine inputs onto a subset of spines of a monkey dlPFC neuron. The yellow dots rep-
resent tyrosine-hydroxylase positive axon terminals; red dots indicate dopamine D1 recep-
tors. An original Goldman-rakic figure based on Krimer et al., 1997 [102].PArAllel BreAkthrouGh BY
AGhAJAnIAn And cohen: the
therAPeutIc eFFects oF 
clonIdIne
While Goldman-Rakic explored the ef-
fects  of  DA  in  primate  dlPFC,  George
Aghajanian studied α2 adrenergic receptor
actions in the brains of opiate-dependent
rats (Figure 4A). He observed that the NE
cells of the locus coeruleus (LC) in the
brainstem (Figure 4B) became overactive
during opiate withdrawal and that the α2
receptor agonist clonidine reduced its fir-
ing through actions at presynaptic α2 re-
ceptors on LC neurons (Figure 4C) [40-42].
The LC provides NE to most of the brain
and spinal cord (Figure 4B); thus, cloni-
dine’s ability to reduce LC cell firing and
NE release has a pervasive effect on the
nervous  system.  This  landmark  finding
continues to guide most research on α2 re-
ceptors to this day. Based on these physio-
logical data in rats, clonidine and other α2
agonists are still being used to treat opiate
withdrawal in humans [43]. However, this
initial finding also led to a breakthrough
treatment for Tourette’s Syndrome [44].
Donald Cohen was a child psychiatrist
(and soon to be Director) of the Yale Child
Study Center (Figure 4D). He was treating
children with Tourette’s Syndrome, a dis-
order in which unwanted movements or ut-
terances (tics) repeatedly disrupt normal
behavior and even endanger patients when
the movements are violent. Cohen brought
Aghajanian with him on rounds to see one
boy with particularly debilitating, self-de-
structive tics. Aghajanian saw a similarity
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Figure 4. the discoveries of clonidine’s effects on lc neuronal firing by George Agha-
janian that led to its therapeutic effects in tourette’s syndrome by donald cohen. A.
George Aghajanian, Professor of Psychiatry and Pharmacology at Yale. Photo courtesy of
Dr. Aghajanian. B. A schematic drawing showing the position of the locus coeruleus in the
human  brainstem,  with  arrows  representing  its  widespread  noradrenergic  projections
throughout the brain and spinal cord. c. The α2 agonist, clonidine (C), reduced LC firing in
opiate-withdrawing rats. Artistically rendered based on Svensson et al., 1975 [40]. d. Don-
ald Cohen, Director of the Yale Child Study Center until 2001. Photo courtesy of Yale uni-
versity. e. Clonidine treatment in a boy with Tourette’s Syndrome reduced the number of tics
compared to baseline. The number of clinician-rated measures of overall Severity of symp-
toms, including motor and phonic tics, decreased with continued clonidine treatment. Artis-
tically rendered based on Cohen et al., 1980 [44]. to the dysregulated movements of opiate
withdrawal and suggested they try cloni-
dine [45]. The medication was successful
in relieving the tics (Figure 4E), and cloni-
dine became one of the first effective treat-
ments for Tourette’s [44]. Later, Hunt and
Cohen tried clonidine in another disinhib-
ited disorder, Attention Deficit Hyperactiv-
ity Disorder (ADHD), again with general
success  [46].  Clonidine  had  significant
sedative side effects, but it was assumed
that the sedation was key to its therapeutic
effects and that clonidine acted by reduc-
ing LC firing to lower arousal in “hyper-
aroused”  patients  [47].  But  research  in
monkeys was about to reveal that α2 re-
ceptors also have powerful effects through
actions in the PFC.
GuAnFAcIne: An unexPected
mechAnIsm
Arnsten and Goldman-Rakic set out to
study the cognitive-enhancing effects of DA
agonists in aged monkeys with naturally oc-
curring DA depletion, but the compound that
produced the most dramatic improvement in
their cognitive performance was not a DA
drug, but clonidine. Following clonidine ad-
ministration, the aged monkeys were almost
asleep  and  yet  performed  near  perfectly
[39]. However, these beneficial cognitive ef-
fects were not due to the expected presy-
naptic effects of clonidine on LC neurons,
but rather arose from actions at post-synap-
tic receptors in the dlPFC [39]. Indeed, de-
struction of the presynaptic sites only made
clonidine’s effects more potent [39,48]. Fur-
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Figure 5. the ʱ2A adrenoceptor agonist guanfacine improves PFc neuronal firing and
cognitive function through actions at ʱ2A receptors on spines in layer III dlPFc neu-
rons. A. top: Systemic administration of guanfacine to aged monkeys improves working
memory performance and is particularly effective in protecting performance from the dele-
terious effects of distracters presented during the delay period. Artistically rendered based
on Arnsten and Contant, 1992 [52]. Bottom: Infusion of guanfacine directly into the rat PFC
improved performance of a working memory task (similar effects were seen with guanfacine
infusions into monkey dlPFC by the Li lab in China [103]). Guanfacine’s enhancing effects
were blocked by co-infusion of the cAMP analog, Sp-cAMPS, demonstrating actions through
cAMP signaling pathways. Artistically rendered based on ramos et al., 2006 [60]. B. Ion-
tophoresis of guanfacine directly onto dlPFC neurons in monkeys performing a working
memory task significantly increased delay-related firing. Firing was suppressed when Sp-
cAMPS was co-applied with the guanfacine. Similar enhancing effects were observed with
the HCN channel blocker ZD7288, which reversed the suppressive effects of the α2 blocker,
yohimbine (not shown). Artistically rendered based on Wang et al., 2007 [62]. c. Double-
label immunogold electron microscopy by Dr. Constantinos Paspalas demonstrating α2A-re-
ceptors co-localized with HCN channels in the spines of layer III dlPFC network synapses.ther research revealed that the α2A-adreno-
ceptor subtype was essential for these ac-
tions  [49]  and  that  the  α2A-preferring
agonist guanfacine can improve working
memory [50,51], attention regulation (Fig-
ure 5A, top) [52,53], and behavioral inhibi-
tion [54] independent of its sedative actions.
Guanfacine is more selective for the α2A re-
ceptor subtype than is clonidine, which also
binds with high affinity to α2B, α2C, and
imidazoline receptors [55,56]. Guanfacine is
weaker  than  clonidine  in  producing  hy-
potension and sedation [50] and has weaker
presynaptic actions in the brain, i.e., it is 10
times less effective in reducing LC firing
and decreasing NE release [57]. However,
guanfacine is more potent than clonidine in
enhancing PFC working memory function
in aged monkeys, suggesting greater effi-
cacy at post-synaptic sites in PFC [50]. Most
recently, guanfacine has been shown to im-
prove impulse control in monkeys perform-
ing  a  delayed  discounting  task,  i.e.,
increasing the ability to resist an immediate,
small reward and instead wait for a larger re-
ward [58]. The PFC is the site of beneficial
drug actions, as guanfacine improves cogni-
tive performance when infused directly into
the rat or monkey PFC (Figure 5A, bottom)
[59-61]. Indeed, guanfacine’s enhancing ef-
fects can even be observed at the cellular
level,  where  application  of  drug  directly
onto dlPFC neurons increases the delay-re-
lated neuronal firing needed for working
memory  [62]  (Figure  5B).  Conversely,
blocking  α2A  receptors  in  the  monkey
dlPFC markedly impairs working memory
[63] and behavioral inhibition [64,65] and
greatly reduces persistent neuronal firing
[62,66], demonstrating that endogenous NE
stimulation of α2A receptors is essential for
PFC regulation of behavior, thought, and
emotion.
IonIc reGulAtIon oF 
PreFrontAl mIcrocIrcuIts: 
vulnerABIlItIes And 
oPPortunItIes
Further research identified the molecu-
lar basis of guanfacine’s enhancing effects in
dlPFC, one that was “upside down and back-
wards” from actions elsewhere in brain. α2A
receptors are coupled to Gi proteins that in-
hibit cAMP signaling. In most brain circuits,
e.g.,  in  hippocampus,  cAMP  strengthens
synaptic connections [67]. However, in PFC,
cAMP weakens persistent firing and impairs
working  memory  [34,62,68-70].  These
seemingly opposite effects arise from cAMP
actions on ion channels that dynamically
alter the strength of PFC network connec-
tions [71]. The pyramidal cell microcircuits
in layer III of dlPFC interconnect on den-
dritic spines via NMDA receptor synapses,
exciting each other to keep information “in
mind” [71]. Immunoelectron microscopy has
revealed α2A receptors on these spines, situ-
ated next to ion channels that can gate net-
work  connections  [62]  (Figure  5C).  Of
special interest are the potassium channels
that are opened by cAMP signaling: HCN
cation channels (Hyperpolarization-activated
Cyclic Nucleotide gated) that are directly in-
fluenced by cAMP and KCNQ channels that
are opened indirectly by cAMP activation of
protein kinase A (PKA) (Figure 1C). Open-
ing these channels by high levels of cAMP
signaling, e.g., during stress exposure or with
α2A receptor blockade, weakens PFC net-
work connections and reduces persistent fir-
ing (Figure 1C), while blockade of HCN
channels restores firing [34,62]. In this way,
exposure to a stressor can rapidly take PFC
“off-line” to switch control of behavior to
more primitive brain circuits that mediate
stress reflexes, such as freezing or fight or
flight habitual responses [72]. This mecha-
nism has survival value when faced with
danger but may be counterproductive when
stressors require thoughtful PFC responses,
e.g., during public speaking or when need-
ing to make a complex decision.
In contrast, NE or guanfacine stimula-
tion  of  α2A  receptors  on  PFC  spines
strengthens PFC network connections by in-
hibiting  cAMP  signaling,  closing  HCN
channels, and increasing delay-related firing
(Figure 1D [62]). As can be seen in Figure 5,
the enhancing effects of guanfacine on both
PFC  persistent  firing  [62]  and  working
memory performance [60] can be reversed
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guanfacine has also been shown to restore
persistent firing in the aged monkey dlPFC
via  inhibition  of  cAMP-HCN  or  KCNQ
channel signaling [73]. Taken together, the
basic  data  show  that  guanfacine  inhibits
cAMP opening of potassium channels on
spines, which increases PFC network firing
and strengthens PFC cognitive control of be-
havior. This process engages PFC circuits to
protect goals from distraction, overcome in-
appropriate habits, and resist impulses to
allow civilized, purposeful behavior. It is re-
markable that these highest order cognitive
operations can be understood at the level of
ion channels.
The  intricate  molecular  mechanisms
needed to precisely regulate PFC network
connectivity are exceptionally vulnerable to
disruption from both environmental and ge-
netic insults. For example, cAMP-PKA sig-
naling  becomes  dysregulated  with
advancing age due to loss of inhibitory in-
fluences on cAMP, and increased cAMP-K+
channel actions lead to reduced persistent
firing  and  impaired  working  memory
[73,74]. A remarkable number of genetic in-
sults in cAMP signaling pathways are asso-
ciated with mental illness. For example, a
taq1 polymorphism in the promoter region
of the gene encoding for dopamine β hy-
droxylase (DβH) leads to reduced DβH ex-
pression, reduced NE synthesis, weaker PFC
executive abilities [75,76], and often a diag-
nosis of ADHD [77-79]. Genetic insults to
cAMP intracellular signaling pathways are
increasingly associated with schizophrenia,
including  the  scaffolding  protein  DISC1
(Disrupted In Schizophrenia) that tethers the
phosphodiesterases PDE4A, PDE4B, and
PDE4D to regulate cAMP concentrations
[80,81], as well as insults to the phosphodi-
esterases themselves [82,83], all of which
are found in the spines of layer III dlPFC
neurons [84] (and Paspalas and Arnsten, un-
published). There are also genetic insults in
receptors  regulating  cAMP  synthesis
(mGluR3, VIPR2) and potassium channels
regulated by cAMP (KCNH2). Alterations
in  these  cAMP-regulating  proteins  may
weaken layer III microcircuits and lead to
the PFC dysfunction which characterizes
this illness.
the therAPeutIc eFFects oF
GuAnFAcIne In PreFrontAl
coGnItIve dIsorders
Based on the research in animals, guan-
facine is now in widespread use for the treat-
ment  of  a  variety  of  PFC  cognitive
disorders. For example, weaker PFC func-
tion is a hallmark of ADHD, particularly
deficits in the right inferior PFC that is spe-
cialized for inhibiting inappropriate actions
[85]. This PFC subregion normally enlarges
as a child matures, but fails to do so in those
with ADHD [86]. Immediate-release guan-
facine  was  first  tested  in  children  with
ADHD by Hunt, based on the successful an-
imal data and his previous experience with
clonidine [87]. It was also tested open label
in ADHD patients with tics at the Yale Child
Study Center [88]. Although guanfacine has
a long half-life in adults, it is rapidly metab-
olized by children, and thus an extended re-
lease formulation was developed (Intuniv™)
and approved by the FDA in 2009 for the
treatment of pediatric ADHD. Guanfacine
helps ADHD patients control their own be-
havior and inhibit inappropriate distractions
and impulses [89,90]. Guanfacine also al-
lows inhibition of inappropriate aggressive
impulses [91], likely through its actions in
ventral PFC. Guanfacine is also in wide-
spread use “off label” to inhibit inappropri-
ate motor and vocal tics in patients with
Tourette’s Syndrome and in children with
ADHD and tics who often cannot take stim-
ulant medications [92]. It is also being tested
in autism spectrum disorders to treat the dis-
inhibited behaviors that often accompany
the social deficits in these disorders [93,94]. 
Immediate-release guanfacine is in ex-
perimental use for a broader number of adult
disorders involving PFC dysfunction. Impor-
tantly, it is helping patients who have trau-
matic brain injury to the PFC for whom there
is great need of treatment [95]. Guanfacine
also has been shown to improve working
memory in patients with schizotypal disorder
with cognitive deficits resembling those in
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tion and metabolism in patients with some
forms of epilepsy [97]. Guanfacine is being
used to treat attentional neglect caused by
stroke [98], which may be related to its atten-
tion-enhancing effects in normal subjects [99].
Studies from the Yale Stress Center are find-
ing that guanfacine can strengthen PFC self-
control during stress and help people quit
smoking (S. McKee, Yale Dept. Psychiatry,
personal communication), and these benefi-
cial effects may extend to other drugs of abuse
as well (R. Sinha, Yale Dept. Psychiatry, per-
sonal  communication).  Finally,  very  low
doses of guanfacine are currently being tested
in the elderly to see if they will ameliorate
age-related cognitive decline in humans as
they do in monkeys (C. van Dyck, Yale Dept.
Psychiatry and Neurology, personal commu-
nication). Thus, guanfacine may be useful for
a breadth of PFC cognitive disorders.
conclusIons And outlook
Many scientists have thought that under-
standing  the  neurobiological  basis  of  our
highest order cognitive functions was beyond
the realm of scientific inquiry, but research at
Yale has shown that it is possible to reveal the
microcircuitry of cognition even at the mo-
lecular level. It is noteworthy that many of
these  key  discoveries  have  been  made
through studies of monkeys engaged in work-
ing memory tasks. Given the great expansion
of the PFC in brain evolution, especially in
the microcircuits of layer III, these break-
throughs may not have occurred without this
invaluable resource. More research is needed
to understand how genetic insults lead to al-
terations in layer III microcircuits, so that we
may develop informed interventions for cog-
nitive disorders.
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